Accuredit and N1 Life Form JV to Develop Gene Editing Delivery Technologies
publication date: Jan 13, 2022
Accuredit Therapeutics (Suzhou) formed a JV with N1 Life of San Jose, CA to develop gene editing therapies. The JV, Napoltec Life Sciences (Suzhou), will develop novel therapeutic drug delivery systems to advance drug candidates toward clinical translation. Founded in 2021, Accuredit focuses its novel gene editing delivery technologies on intracellular targets. N1 Life, another new company, also develops cutting edge drug delivery technologies. Its technology comes from the innovative drug delivery research lab of Professor Paul A. Wender, Francis W. Bergstrom Professor of Chemistry & Chemical & System Biology at Stanford. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.